Study Group: Non-Electrophysiologist Cardiologists (US)
Council Members in this Study Group: 853
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Harold BaysPresident and Medical Director
L-MARC Research Center
Harold Bays, MD, FACP, FACE, is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center (L-MARC), a metabolic clinical research facility that has conducted over 400 phase I-IV clinical trials, including studies of all...
- Daniel Fisher
Cardiologist
NEW YORK UNIVERSITY (INC)Daniel Fisher, MD, FACC, FACP, is a Cardiologist at NYU Medical Center. He has a private practice in Cardiology and specializes in non-invasive cardiology. Dr. Fisher is board certified in Internal Medicine, Cardiovascular Diseases, and Nuclear Cardiology....
Hossein ArdehaliAssistant Professor
Northwestern University, Feinberg School of MedicineHossein Ardehali, MD, PhD, is Assistant Professor of Medicine at Feinberg Cardiovascular Institute in Illinois. His specialties include lipid metabolism, preventive cardiology, electrophysiology and heart failure. Dr. Ardehali's basic science research...
- Charles O'Shaughnessy
Director of Interventional Cardiology
NORTH OHIO HEART CENTER, INCCharles O'Shaughnessy, MD, is the Director of Interventional Cardiology at North Ohio Heart Center, Ohio. Dr. O'Shaughnessy's clinical interests are in interventional cardiology including balloon angioplasty, laser directional atherectomy, stent placement,...
Rohit AroraProfessor of Medicine
Finch University of Health Science-Chicago Medical SchoolRohit Arora, MD, FACC, FAHA, FASCI, FACP, is Professor of Medicine and Professor of Physiology and Biophysics at Chicago Medical School. He is also the Chairman of Cardiology and Associate Chairman of Medicine in the Department of Medicine. Previously,...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
September 30, 2009
Controls to blood sugar 'cuts stroke risk' | www.barchester.com
There have been many epidemiologic studies showing a very tight correlation between baseline A1c and cardiovascular mortalityDespite this, five major randomized prospective studies have failed to show any macrovascular benefit for tighter glucose controlThe logical conclusion is that glucose is, therefore, a marker for increased mortality but not a modifiable risk factor thereofThis is why FDA has mandated cardiovascular safety for new antidiabetic agentsData dredging persists, however
-
If it seems too good to be true...it probably is.
December 9, 2008
Analysis by: Joshua Feuer, Owner,Generic Heart Drugs as Good as Brand-Name Counterparts | www.washingtonpost.com
This article implies that physician's have no justifiable reason for prescribing brand-name drugs. Unfortunately, it's not that simple.
-
December 8, 2008
Analysis by: Joshua Feuer, Owner,There is a question of bias in this study. It is not prospective, not randomized and not blinded and thus no valid conclusions can be made. The study should be ignored. It will have no impact on sales.
-
Outsourcing of compassionate use of drugs?
January 18, 2008
Analysis by: Dan Streja, Clinical Professor of Medicine,No right to experimental drugs for dying patients: Supreme Court | news.yahoo.com
The Supreme Court has rejected the use of experimental drugs by the dying patients on the grounds that "The framers (of the US constitution) understood that the pursuit of life is an inalienable right that should not be abridged without due process of law." Over the years our patients with terminal illness have traveled outside the US to purchase hope when our management was offering none. Although in the majority of cases the hope was unjustified, the current decision will encourage healthcare providers residing outside the US to advertise for their services through the internet. The issue should be addressed by the legislators sooner rather than later. Drugs who improve quality of life, awaiting approval for survival indication or drugs looking promising in early clinical trials could be made available to dying patients with informed consent addressing our limitations.
-
November 23, 2007
Study Shows Weight-Loss Drug Rimonabant is Associated with Severe Adverse Psychiatric Events | pharmalive.com
The pooled analysis of Rimonabant trials point to a significant increase in psychiatric disorders. These studies also point to significant improvements in markers of cardiovascular risk. Risks versus benefits must be considered before the final decision is made on this class of medications.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Owner
- Physician - Division Head
- Partner
Related Study Groups
GLG Live Meetings with this Study Group's Leading Experts (?)
August 21, 2008 | Palo Alto
GLG Seminar: (Palo Alto) Heart FailureMay 22, 2008 | Boston
GLG Seminar: Diabetes and ObesityMarch 28, 2008 | Boston
GLGi: Lipid ManagementTeleconference: Cholesterol War – Merck’s Zetia vs. Abbott’s Niaspan (10:15 AM EST / 15:15 GMT)
11/17/2009
Listen to Archive